 |
24 Diseases |  |
12 Trials |
|
12 Trials |  |
871 News |  |
| «12345678910111213» |
- ||||||| brivaracetam / Generic mfg.
Trial completion: BRITE: Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy (clinicaltrials.gov) - Apr 24, 2019
P3, N=767, Completed, Sponsor: UCB BIOSCIENCES, Inc.
Active, not recruiting --> Completed
- | Briviact (brivaracetam) / UCB
Review, Journal: Brivaracetam add-on therapy for drug-resistant epilepsy. (Pubmed Central) - Apr 18, 2019
Consequently, these findings are mainly applicable to adult patients with drug-resistant focal epilepsy. Future research should thus focus on investigating the tolerability and efficacy of brivaracetam during longer-term follow-up, and should also assess the efficacy and tolerability of add-on brivaracetam in managing other types of seizures and its use in other age groups.
- ||||| brivaracetam / Generic mfg.
Enrollment change: A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (clinicaltrials.gov) - Apr 11, 2019
P3, N=227, Enrolling by invitation, Sponsor: UCB Biopharma S.P.R.L.
Future research should thus focus on investigating the tolerability and efficacy of brivaracetam during longer-term follow-up, and should also assess the efficacy and tolerability of add-on brivaracetam in managing other types of seizures and its use in other age groups. N=124 --> 227
- | Briviact (brivaracetam) / UCB
Clinical, Journal: Brivaracetam in the treatment of patients with epilepsy (Pubmed Central) - Apr 10, 2019
The authors present conclusions of the Russian leading epileptologists on perspectives of using BRV in different populations of epileptic patients. The use of BRV is able to provide long-term efficacy in terms of seizure control, is well tolerated, keeps quality of life and social activity of people with epilepsy.
- | Briviact (brivaracetam) / UCB
Clinical, Retrospective data, Journal: Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program. (Pubmed Central) - Apr 7, 2019
P3
This post-hoc analysis does not support an association between CBZ-E levels and TEAEs potentially associated with CBZ-E toxicity, or with increases in efficacy. Overall, current evidence does not suggest that BRV dose adjustment is required with concomitant CBZ.
- | Briviact (brivaracetam) / UCB
Journal: Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50-mg Film-Coated Tablet. (Pubmed Central) - Mar 29, 2019
The geometric means ratios (oral solution vs tablet) and 90% confidence intervals for Cmax , area under the plasma concentration-vs-time curve from time 0 to the last observed time point (AUCt ), and area extrapolated to infinity (AUC∞ ) were 1.06 (0.99 to 1.13), 0.99 (0.97 to 1.01), and 0.98 (0.96 to 1.00), respectively. All values were within the 0.80 to 1.25 range, indicating that the oral solution and tablet are bioequivalent.
- | Briviact (brivaracetam) / UCB
Journal: A Viedma ripening route to an enantiopure building block for Levetiracetam and Brivaracetam. (Pubmed Central) - Mar 27, 2019
This approach is based on the rational design and application of a Viedma ripening process. The practical potential of the process is demonstrated on a large scale.
- ||| brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (clinicaltrials.gov) - Mar 20, 2019
P3, N=124, Enrolling by invitation, Sponsor: UCB Biopharma S.P.R.L.
The practical potential of the process is demonstrated on a large scale. Trial completion date: Nov 2022 --> May 2024 | Trial primary completion date: Nov 2022 --> May 2024
- | brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures (clinicaltrials.gov) - Mar 1, 2019
P2/3, N=42, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Nov 2022 --> May 2024 | Trial primary completion date: Nov 2022 --> May 2024 Trial completion date: Jan 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Nov 2021
- |||| brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy (clinicaltrials.gov) - Feb 11, 2019
P3, N=504, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Jan 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Nov 2021 Trial completion date: Mar 2020 --> Aug 2021 | Trial primary completion date: Jan 2020 --> Jul 2021
- brivaracetam / Generic mfg.
Enrollment open: A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (clinicaltrials.gov) - Jan 8, 2019
P3, N=10, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Mar 2020 --> Aug 2021 | Trial primary completion date: Jan 2020 --> Jul 2021 Not yet recruiting --> Recruiting
- | brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: BASE: Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (clinicaltrials.gov) - Nov 6, 2018
P=N/A, N=430, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Not yet recruiting --> Recruiting Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020
- | padsevonil (UCB0942) / UCB
New P1 trial: A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil (clinicaltrials.gov) - Oct 2, 2018
P1, N=28, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
- | brivaracetam / Generic mfg.
New P3 trial: A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (clinicaltrials.gov) - Sep 26, 2018
P3, N=10, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
- | brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (clinicaltrials.gov) - Aug 20, 2018
P3, N=600, Enrolling by invitation, Sponsor: UCB Pharma
Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> Jul 2020 Trial completion date: Oct 2021 --> Jan 2024 | Trial primary completion date: Oct 2021 --> Dec 2023
- | brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: BRITE: Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy (clinicaltrials.gov) - Aug 2, 2018
P3, N=767, Active, not recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Trial completion date: Oct 2021 --> Jan 2024 | Trial primary completion date: Oct 2021 --> Dec 2023 Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019
- | brivaracetam / Generic mfg.
Phase classification, Adverse events: Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV) (clinicaltrials.gov) - Jul 11, 2018
P3b, N=29, Completed, Sponsor: UCB Pharma SA
Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Dec 2018 --> Mar 2019 Phase classification: P3 --> P3b
- || brivaracetam / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy (clinicaltrials.gov) - Jun 6, 2018
P2, N=50, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Phase classification: P3 --> P3b Not yet recruiting --> Recruiting | Trial completion date: Feb 2020 --> Jul 2020 | Trial primary completion date: Feb 2020 --> Jul 2020
- | brivaracetam / Generic mfg.
New trial: Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy (clinicaltrials.gov) - May 27, 2018
P=N/A, N=0, Available, Sponsor: UCB Biopharma S.P.R.L.
- ||| brivaracetam / Generic mfg.
New trial: Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study (clinicaltrials.gov) - May 8, 2018
P=N/A, N=200, Not yet recruiting, Sponsor: Centre hospitalier de l'Universit
- || brivaracetam / Generic mfg.
Phase classification: BASE: Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (clinicaltrials.gov) - Apr 6, 2018
P, N=430, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Not yet recruiting --> Recruiting | Trial completion date: Feb 2020 --> Jul 2020 | Trial primary completion date: Feb 2020 --> Jul 2020 Phase classification: P=N/A --> P
- | brivaracetam / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures (clinicaltrials.gov) - Mar 20, 2018
P2/3, N=42, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
Phase classification: P=N/A --> P Trial completion date: Dec 2019 --> Nov 2020 | Initiation date: Nov 2017 --> Mar 2018 | Trial primary completion date: Oct 2019 --> Oct 2020
- | brivaracetam / Generic mfg.
Trial initiation date: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy (clinicaltrials.gov) - Mar 3, 2018
P2, N=50, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Dec 2019 --> Nov 2020 | Initiation date: Nov 2017 --> Mar 2018 | Trial primary completion date: Oct 2019 --> Oct 2020 Initiation date: Jan 2018 --> Feb 2018
- ||||| brivaracetam / Generic mfg.
Trial initiation date: Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (clinicaltrials.gov) - Mar 3, 2018
P3, N=600, Enrolling by invitation, Sponsor: UCB Pharma
Initiation date: Jan 2018 --> Feb 2018 Initiation date: Jul 2011 --> Aug 2011
- brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy (clinicaltrials.gov) - Feb 20, 2018
P2, N=50, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
Initiation date: Jul 2011 --> Aug 2011 Trial primary completion date: Jan 2021 --> Feb 2020 | Trial completion date: Jan 2021 --> Feb 2020
- | brivaracetam / Generic mfg.
New P2 trial: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy (clinicaltrials.gov) - Jan 23, 2018
P2, N=50, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
- || brivaracetam / Generic mfg.
Trial primary completion date: BASE: Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (clinicaltrials.gov) - Jan 4, 2018
P=N/A, N=430, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial primary completion date: Jan 2021 --> Feb 2020 | Trial completion date: Jan 2021 --> Feb 2020 Trial primary completion date: Mar 2019 --> Dec 2019
- | brivaracetam / Generic mfg.
Trial completion, Trial primary completion date: A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers (clinicaltrials.gov) - Oct 30, 2017
P1, N=13, Completed, Sponsor: UCB Pharma
Trial primary completion date: Mar 2019 --> Dec 2019 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017
- ||| brivaracetam / Generic mfg.
New P2/3 trial: A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures (clinicaltrials.gov) - Oct 30, 2017
P2/3, N=42, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
- ||||||| brivaracetam / Generic mfg.
Trial completion: This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment (clinicaltrials.gov) - Oct 2, 2017
P3, N=668, Completed, Sponsor: UCB PHARMA Inc. (US)
Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Sep 2017 Active, not recruiting --> Completed
- |||| brivaracetam / Generic mfg.
Trial primary completion date: BRITE: Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy (clinicaltrials.gov) - Sep 8, 2017
P3, N=767, Active, not recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Dec 2018
- |||| brivaracetam / Generic mfg.
Trial primary completion date: Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy (clinicaltrials.gov) - Sep 1, 2017
P3, N=853, Active, not recruiting, Sponsor: UCB Pharma
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Mar 2018 --> Feb 2019
- |||||| brivaracetam / Generic mfg.
Enrollment open: A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy (clinicaltrials.gov) - Aug 24, 2017
P3, N=504, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial primary completion date: Mar 2018 --> Feb 2019 Not yet recruiting --> Recruiting
- |||||| brivaracetam / Generic mfg.
Enrollment open: A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (clinicaltrials.gov) - Aug 21, 2017
P3, N=124, Enrolling by invitation, Sponsor: UCB Biopharma S.P.R.L.
Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
- |||||||||| brivaracetam / Generic mfg.
New P3 trial: A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization (clinicaltrials.gov) - Aug 15, 2017
P3, N=124, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
- brivaracetam / Generic mfg.
Enrollment open, Trial primary completion date: A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers (clinicaltrials.gov) - May 12, 2017
P1, N=16, Recruiting, Sponsor: UCB Pharma
Not yet recruiting --> Enrolling by invitation Completed --> Recruiting | Trial primary completion date: Apr 2016 --> Jun 2017
- ||||||| brivaracetam / Generic mfg.
Trial completion: An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam (clinicaltrials.gov) - Apr 13, 2017
P3, N=108, Completed, Sponsor: UCB Pharma
Completed --> Recruiting | Trial primary completion date: Apr 2016 --> Jun 2017 Active, not recruiting --> Completed
- |||| brivaracetam / Generic mfg.
Trial primary completion date: This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment (clinicaltrials.gov) - Apr 7, 2017
P3, N=668, Active, not recruiting, Sponsor: UCB PHARMA Inc. (US)
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Jul 2017
- |||| brivaracetam / Generic mfg.
Trial primary completion date: Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy (clinicaltrials.gov) - Mar 29, 2017
P3, N=853, Active, not recruiting, Sponsor: UCB Pharma
Trial primary completion date: Mar 2017 --> Jul 2017 Trial primary completion date: Dec 2017 --> Mar 2018
- |||||||||| brivaracetam / Generic mfg.
New P3 trial: A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy (clinicaltrials.gov) - Mar 19, 2017
P3, N=504, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
- |||| brivaracetam / Generic mfg.
Trial primary completion date: Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy (clinicaltrials.gov) - Feb 13, 2017
P3, N=853, Active, not recruiting, Sponsor: UCB Pharma
Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: Jan 2017 --> Dec 2017
- |||| brivaracetam / Generic mfg.
Enrollment open: A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting (clinicaltrials.gov) - Feb 11, 2017
P2, N=60, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial primary completion date: Jan 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- |||| brivaracetam / Generic mfg.
Trial primary completion date: An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam (clinicaltrials.gov) - Jan 18, 2017
P3, N=108, Active, not recruiting, Sponsor: UCB Pharma
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Mar 2017
- |||| brivaracetam / Generic mfg.
Trial primary completion date: This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment (clinicaltrials.gov) - Jan 13, 2017
P3, N=668, Active, not recruiting, Sponsor: UCB PHARMA Inc. (US)
Trial primary completion date: Oct 2016 --> Mar 2017 Trial primary completion date: Dec 2016 --> Mar 2017
- ||||| brivaracetam / Generic mfg.
New P2 trial: A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting (clinicaltrials.gov) - Jan 13, 2017
P2, N=60, Not yet recruiting, Sponsor: UCB Biopharma S.P.R.L.
- |||| brivaracetam / Generic mfg.
Trial primary completion date: BRITE: Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy (clinicaltrials.gov) - Sep 21, 2016
P3, N=767, Active, not recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Nov 2016 --> Dec 2017
- || brivaracetam / Generic mfg.
Trial completion: Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy (clinicaltrials.gov) - Aug 19, 2016
P3b, N=26, Completed, Sponsor: UCB Pharma SA
Trial primary completion date: Nov 2016 --> Dec 2017 Active, not recruiting --> Completed
- |||| brivaracetam / Generic mfg.
Trial primary completion date: Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy (clinicaltrials.gov) - Jun 10, 2016
P3, N=600, Enrolling by invitation, Sponsor: UCB Pharma
Active, not recruiting --> Completed Trial primary completion date: Sep 2017 --> Oct 2021
- |||| brivaracetam / Generic mfg.
Trial primary completion date: An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam (clinicaltrials.gov) - Jun 5, 2016
P3, N=108, Active, not recruiting, Sponsor: UCB Pharma
Trial primary completion date: Sep 2017 --> Oct 2021 Trial primary completion date: Dec 2017 --> Oct 2016
- brivaracetam / Generic mfg.
Phase classification: Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy (clinicaltrials.gov) - Jun 2, 2016
P3b, N=26, Active, not recruiting, Sponsor: UCB Pharma SA
Trial primary completion date: Dec 2017 --> Oct 2016 Phase classification: P3 --> P3b